Merck & Co Invests $700 Million to Acquire Rights to Broad-Cancer Antibody-Drug Conjugate Asset

Merck & Co (MSD) has finalized a $700 million agreement to expand its pipeline in antibody-drug conjugates (ADCs), a therapeutic modality gaining traction in oncology. The deal underscores the continued interest in ADCs within the pharmaceutical industry, as companies seek innovative approaches to cancer treatment.

The transaction involves MSD securing rights to a broad-cancer ADC asset, which is designed to target multiple cancer types. ADCs combine monoclonal antibodies with cytotoxic drugs, enabling precise delivery of chemotherapy agents directly to cancer cells while minimizing damage to healthy tissues. This approach has shown promise in improving efficacy and reducing side effects compared to traditional treatments. MSD’s investment reflects its commitment to advancing research and development in this area, aligning with broader trends in oncology drug innovation.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 5, 2025

Related posts:

Circio CEO Erik Wiklund Discusses Workforce Dynamic Shifts in Pharma Post-COVID-19 Johnson & Johnson Releases Data on Akeega Showing Effectiveness Against HRR Gene Mutations in Early-Stage Prostate Cancer Epic Systems Launches AI Tool Integrated into Its EHR Platform, Challenging Health Tech Startups Nektar Therapeutics Stock Rises Amid Speculation of Eli Lilly Buyout

Author

GOAI